A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

This study has been completed.
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000652
First received: November 2, 1999
Last updated: October 31, 2012
Last verified: October 2012

November 2, 1999
October 31, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00000652 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

To assess the safety and tolerance of the combination of zidovudine (AZT) and didanosine (ddI) in children with HIV infection.

New approaches to using available agents may provide increased or improved treatment options for AIDS. Combination therapy is expected to play a major role in improving survival and quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most extensively evaluated and for which the evidence for antiretroviral effectiveness is strongest.

New approaches to using available agents may provide increased or improved treatment options for AIDS. Combination therapy is expected to play a major role in improving survival and quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most extensively evaluated and for which the evidence for antiretroviral effectiveness is strongest.

Patients take AZT and ddI on an empty stomach; ddI is taken 2 minutes after taking antacid. Part A patients receive AZT plus ddI each at ranging doses. Patients in part B may receive a higher dose of ddI than patients in part A. The first patients enrolled are given the lowest dose. Subsequent patients receive increasingly higher doses until a dose limiting toxicity occurs.

Interventional
Phase 1
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
HIV Infections
  • Drug: Zidovudine
  • Drug: Didanosine
Not Provided
Mueller BU, Pizzo PA, Farley M, Husson RN, Goldsmith J, Kovacs A, Woods L, Ono J, Church JA, Brouwers P, et al. Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. J Pediatr. 1994 Jul;125(1):142-6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
85
November 1995
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Corticosteroids for treatment of lymphocytic interstitial pneumonitis.

Concurrent Treatment:

Allowed:

  • Intravenous hyperalimentation.

Patients must have the following:

  • P-2 class symptomatic HIV infection as defined by CDC OR who are asymptomatic but whose total CD4 cell count is < 500 cells/mm3.
  • Freedom from significant active opportunistic or other infection requiring specific therapy.

Part B patients:

  • Prior treatment with zidovudine (AZT) that was discontinued because of hematologic toxicity.
  • Availability of a parent or legal guardian who is sufficiently reliable to give informed consent and follow necessary study procedures including administration of medications and return for follow-up visits.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.
  • History of acute or chronic pancreatitis.

Patients with the following are excluded:

  • Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.
  • History of acute or chronic pancreatitis.

Prior Medication:

Excluded:

  • Antiretroviral or other antiviral agent within 14 days of entry into study.
  • Immunomodulating agents, cytolytic chemotherapeutic agents, corticosteroids within 30 days (except for lymphocytic interstitial pneumonitis).

Part A patients:

  • Zidovudine (AZT) or didanosine (ddI).

Part B patients:

  • Didanosine (ddI).

Prior Treatment:

Excluded:

  • Radiation therapy within 30 days.
  • Intravenous immunoglobulin preparations within 14 days of entry into study.
Both
3 Months to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000652
ACTG 176, NCI 91 C-09
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: PA Pizzo
Study Chair: RN Husson
National Institute of Allergy and Infectious Diseases (NIAID)
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP